Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-Naïve Patients
- M D Anderson Cancer Center, Department of Diagnostic Radiology (United States)
- Klinikum Karlsruhe, Academic Teaching Hospital of the University of Freiburg, Medical Clinic III, Department of Hematology, Oncology, Infectious Disease and Palliative Medicine (Germany)
- Klinikum Karlsruhe, Academic Teaching Hospital of the University of Freiburg, Department of General and Visceral Surgery (Germany)
- Klinikum Karlsruhe, Academic Teaching Hospital of the University of Freiburg, Department of Nuclear Medicine (Germany)
IntroductionTo investigate prognostic factors in unresectable intrahepatic cholangiocarcinoma (ICC) therapy-naïve patients after yttrium-90 (Y-90) radioembolization (RE) therapy.Materials and MethodsBetween 2005 and 2016, 21 patients with ICC were treated with Y-90 RE only and their survival data were analyzed. Patients were stratified and response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.ResultThe overall median survival was 15 months. Survival was significantly (p = 0.009) prolonged in patients with tumor burden of ≤ 25% (n = 8, OS 37.5 months) versus those with a tumor burden of 25–50% (n = 13, OS 15 months). The other variables: tumor morphology (infiltrative vs. peripheral), tumor distribution (solitary vs. multifocal), lobes involved (unilobar vs. bilobar), FDG PET status (FDG avid vs. non-avid), RE treatment sessions (1 session vs. 2 sessions), metastases (metastasis vs. no metastasis) and RECIST criteria, had no significant impact on survival.ConclusionTumor burden represents a key prognostic factor of survival in therapy-naïve patients with unresectable ICC treated with Y-90 RE therapy only.
- OSTI ID:
- 22750030
- Journal Information:
- Cardiovascular and Interventional Radiology, Vol. 41, Issue 5; Other Information: Copyright (c) 2018 Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); http://www.springer-ny.com; Country of input: International Atomic Energy Agency (IAEA); ISSN 0174-1551
- Country of Publication:
- United States
- Language:
- English
Similar Records
Chemoembolization with Degradable Starch Microspheres for Treatment of Patients with Primary or Recurrent Unresectable, Locally Advanced Intrahepatic Cholangiocarcinoma: A Pilot Study
Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma